openPR Logo
Press release

Investigation for Investors in shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) announced

07-24-2019 06:24 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation for investors in Kezar Life Sciences, Inc. (NASDAQ: KZR) shares over potential securities laws violations.

An investigation for investors in Kezar Life Sciences, Inc. (NASDAQ: KZR) shares over potential securities laws violations.

Kezar Life Sciences, Inc. (NASDAQ: KZR) is under investigation over potential securities laws violations in connection with certain financial statements.

Investors who purchased shares of Kezar Life Sciences, Inc. (NASDAQ: KZR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Kezar Life Sciences, Inc. (NASDAQ: KZR) concerning whether a series of statements by Kezar Life Sciences, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Francisco, CA based Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of small molecule therapeutics to treat unmet needs in autoimmunity and cancer in the United States. Kezar Life Sciences, Inc. went public in June 2018 and sold 5 million shares at $15 per share.

Since then, shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) declined to as low as $5.65 per share on July 18, 2019.

On July 23, 2019, NASDAQ: KZR shares closed at $6.00 per share.

Those who purchased shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation for Investors in shares of Kezar Life Sciences, Inc. (NASDAQ: KZR) announced here

News-ID: 1810605 • Views:

More Releases from Shareholders Foundation

Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: JHX) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with James Hardie Industries plc (NYSE: …
An investor, who purchased shares of James Hardie Industries plc (NYSE: JHX), filed a lawsuit over alleged violations of Federal Securities Laws by James Hardie Industries plc in connection with certain allegedly false and misleading statements. Investors who purchased shares of James Hardie Industries plc (NYSE: JHX) have certain options and for certain investors are short and strict deadlines running. Deadline: December 23, 2025. NYSE: JHX investors should contact the Shareholders
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT)
Investigation announced for Long-Term Investors in SelectQuote, Inc. (NYSE: SLQT …
An investigation on behalf of current long-term investors in shares of SelectQuote, Inc. (NYSE: SLQT) concerning potential breaches of fiduciary duties by certain directors and officers of SelectQuote, Inc. was announced. Investors who are current long term investors in SelectQuote, Inc. (NYSE: SLQT) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherapeutics (NASDAQ: MLTX)
Lawsuit filed for Investors who lost money with shares of MoonLake Immunotherape …
An investor, who purchased shares of MoonLake Immunotherapeutics (NASDAQ: MLTX), filed a lawsuit over alleged violations of Federal Securities Laws by MoonLake Immunotherapeutics in connection with certain allegedly false and misleading statements. Investors who purchased a significant amount of shares of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, have certain options and for certain investors are short and strict deadlines running. Deadline: December 15, 2025. NASDAQ:
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
Dow Inc. (NYSE: DOW) Investor Alert: Deadline in Lawsuit on October 28, 2025
A deadline is coming up on October 28, 2025 in the lawsuit filed for certain investors of Dow Inc. (NYSE: DOW) over alleged securities laws violations by Dow Inc. Investors who purchased shares of Dow Inc. (NYSE: DOW) have certain options and there are strict and short deadlines running. Deadline: October 28, 2025. Dow Inc. (NYSE: DOW) stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Kezar

Dermatomyositis Market Generated Opportunities, Future Scope 2025-2032 | CSL Lim …
The Latest study titled Dermatomyositis Market 2025, published by Coherent Market Insights, provides valuable insights into both regional and global markets projected to grow in value from 2025 to 2032. The comprehensive research delves into the evolving market dynamics, value chain analysis, prominent investment areas, competitive landscape, regional outlook, and key market segments. It also offers a thorough assessment of the global market's drivers and constraints. Additionally, the report highlights
Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Corbus …
United States, Nevada, Las Vegas, DelveInsight's 'Dermatomyositis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain. Download a free sample report @ https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Dermatomyositis Pipeline Report Over 10+ Dermatomyositis pipeline therapies are in various stages of development, and
Autoimmune Hemolytic Anemia Therapeutics Market Report Analysis, Research Studie …
DataM Intelligence has published a new research report on "Autoimmune Hemolytic Anemia Therapeutics Market Size 2024". The report explores comprehensive and insightful Information about various key factors like Regional Growth, Segmentation, CAGR, Business Revenue Status of Top Key Players and Drivers. The purpose of this report is to provide a telescopic view of the current market size by value and volume, opportunities, and development status. Get a Free Sample Research
Dermatomyositis Clinical Trials | A Drug Pipeline Analysis Report 2024 | Corbus …
DelveInsight's 'Dermatomyositis Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Dermatomyositis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Dermatomyositis pipeline domain. Download a free sample report @ https://www.delveinsight.com/report-store/dermatomyositis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr Key Takeaways from the Dermatomyositis Pipeline Report Over 10+ Dermatomyositis pipeline therapies are in various stages of development, and their anticipated acceptance in the
Europe Autoimmune Hemolytic Anemia Therapeutics Market Insights and Growth Oppor …
A new Report by DataM Intelligence, titled "Europe Autoimmune Hemolytic Anemia Therapeutics Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031,"" offers a comprehensive analysis of the industry, which comprises insights on the Europe Autoimmune Hemolytic Anemia Therapeutics market analysis. The report also includes competitor and regional analysis, and contemporary advancements in the market. This report has a complete table of contents, figures, tables, and charts, as well as insightful
Latest Report: Warm Autoimmune Hemolytic Anemia Therapy Market Is Expected Signi …
A thorough analysis of Warm Autoimmune Hemolytic Anemia Therapy Market statistics about the current as well as emerging trends offers clarity regarding the Warm Autoimmune Hemolytic Anemia Therapy Market dynamics. The report includes Porter's Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable